Abstract

BACKGROUND: Hepatitis C virus (HCV) infection is widespread, abhorrently under-diagnosed, and radically under-treated. Globally, infection with HCV is a major cause of acute hepatitis and chronic liver disease. Therefore, novel HCV inhibitors are required for the treatment of the HCV infected patients.
OBJECTIVE AND
PERSPECTIVES: This review gives the detailed knowledge of upcoming therapy such as NS5B polymerase inhibitors that are urgently needed.
CONCLUSION: In the past decade, intensive hard work has focused on the discovery of both structural and nonstructural inhibitors of the HCV NS5B polymerase. These demanding efforts have resulted in various promising agents advancing in clinical development with emphasis on clinical efficacy and impact for future combination studies.

Links

Aggregator Full Text

Authors

Varshney J, Sharma PK, Sharma A

Institution

Department of Pharmaceutical Technology, Meerut Institute of Engineering and Technology, Baghpat Bypass Crossing, Delhi-Haridwar Highway, NH-58, Meerut, UP, India. jonishvarshney@gmail.com

Source

European review for medical and pharmacological sciences 16:5 2012 May pg 667-71

MeSH

Animals
Antiviral Agents
Drug Design
Drug Resistance, Viral
Enzyme Inhibitors
Hepacivirus
Hepatitis C
Humans
Molecular Structure
RNA, Viral
Structure-Activity Relationship
Treatment Outcome
Viral Load
Viral Nonstructural Proteins

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

22774409